Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04925947 · ClinicalTrials.gov registry record · Phase 2
A Study of KN046 in Patients With Thymic Carcinoma Who Failed Immune Checkpoint Inhibitors
A Phase 2 study, sponsored by Weill Medical College of Cornell University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
NCT04925947: Clinical Trial Phase 2 study, sponsored by Weill Medical College of Cornell University.
NCT04925947 is a Phase 2 study that was terminated before completion, run by Weill Medical College of Cornell University. The registered enrollment target is 4 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04925947, a Phase 2 study, was terminated before completion, sponsored by Weill Medical College of Cornell University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
Study Summary
This study will assess the safety and efficacy of the study drug KN046 in patients with advanced thymic carcinoma who progressed after prior treatment with immune checkpoint inhibitor therapy.
Primary Outcome
Disease response rate
Interventions
- DRUG KN046
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2021-12-13 |
| Est. Completion | 2023-05-05 |
| Phase | Phase 2 |
Why NCT04925947 stopped before completion
NCT04925947 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 1 intervention - of which KN046 is the first listed.
NCT04925947 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04925947 about?
NCT04925947 is a clinical study titled "A Study of KN046 in Patients With Thymic Carcinoma Who Failed Immune Checkpoint Inhibitors". This study will assess the safety and efficacy of the study drug KN046 in patients with advanced thymic carcinoma who progressed after prior treatment with immune checkpoint inhibitor therapy.
What is the current status of trial NCT04925947?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2021-12-13. Estimated completion is 2023-05-05.
What interventions are being tested in trial NCT04925947?
The interventions under investigation include: KN046 (DRUG).
Who is sponsoring clinical trial NCT04925947?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04925947's enrollment target sits among peer trials
4 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI